Loading color scheme


Aclys Bio and Genmab Enter Research and Commercial License Option Agreement to Develop Proprietary Aclys Antibodies Against an Undisclosed Target

Aclys Bio Corp (“Aclys”), a company discovering and developing precision biologics for the treatment of cancer, earlier this month announced a new exclusive research and commercial license option agreement with Genmab A/S (Nasdaq: GMAB), an international biotech company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Under the terms of the agreement, Genmab secures exclusive rights to Aclys antibodies (specific to an undisclosed target) for further research in conjunction with Genmab’s proprietary platforms. Genmab is also granted the option to advance development and commercialization of resulting products.

Aclys has built a broad range of antibodies using its PILA™ platform to create targeted therapeutics for solid tumors. The agreement with Genmab recognizes the capability of the Aclys PILA platform to identify novel precision targets.

“We have differentiated, high value targets, unique antibody engineering capabilities, and a team that has delivered some of the most valuable monoclonal antibodies currently in development.”, said Dr. Tony Cooper, Aclys Cofounder and CEO. “This agreement with Genmab is integral to advancing our goal of delivering life-saving therapies to patients.” Aclys is a leader in the emerging field of precision immune medicine. Aclys utilizes a proprietary set of patient molecular data to select differentiated targets and create precision biologics with the safety profile and response rates only achievable with precision biologics.

About Aclys Bio

Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a set of novel precision and immune-oncology targets from the tumor molecular profiles of tens of thousands of cancer patients and is building antibody-based therapies against each target, both for internal development, and for partnership. Aclys's Precision ImmunoLogical Antibody™ discovery platform (PILA™ or PILA Platform™) enables Aclys’s rapid antibody engineering and optimization. The resultant new class of developable precision biologics has unique potential to decrease clinical trial times, costs, and risk, while improving trial success rates and ultimately, patient lives. For more information, please visit Aclys.bio.